Erika Hamilton
SCRI Development Innovations, LLC · Tennessee Oncology · SCRI
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Erika Hamilton as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05748834 · Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerSCRI Development Innovations, LLC · recruiting · Breast Cancer · study chair
- Ph1NCT04991480 · A Study of ART4215 for the Treatment of Advanced or Metastatic Solid TumorsArtios Pharma Ltd · completed · Advanced Cancer, Metastatic Cancer, Breast Cancer · study chair
- Ph2NCT04699630 · A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast CancerSCRI Development Innovations, LLC · completed · Metastatic Breast Cancer, Locally Advanced Breast Cancer · study chair
- Ph1/Ph2NCT04042116 · A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorClovis Oncology, Inc. · suspended · Advanced Solid Tumor, Gynecologic Cancer · principal investigator
- N/ANCT02436772 · Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBCSCRI Development Innovations, LLC · completed · Metastatic Breast Cancer · principal investigator
- Ph1NCT02248090 · AZD9496 First Time in Patients Ascending Dose StudyAstraZeneca · completed · ER+ HER2- Advanced Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:20 UTC. The ranking covers the 200 most relevant of 145 PubMed records, and a shared surname and initials can bring in a namesake. All 145 on PubMed
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.N Engl J Med · 20201,043 citationsRCR 46.1
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.N Engl J Med · 20221,024 citationsRCR 73.8
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).J Clin Oncol · 2020882 citationsRCR 37.6
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.Breast Cancer Res Treat · 2018630 citationsRCR 20.9
- 606 citationsRCR 55.2
- 458 citationsRCR 17.8
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.JAMA Oncol · 2019397 citationsRCR 13.6
- 306 citationsRCR 16.2
- 296 citationsRCR 14.0
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.JAMA Oncol · 2019234 citationsRCR 8.0